SELLAS Life Sciences Provides Webcast Information for Phase 3 REGAL Study Update on November 14, 2022
SELLAS Life Sciences Group (NASDAQ: SLS) will host a virtual investor event on November 14, 2022, at 8:30 a.m. ET, to discuss the Phase 3 REGAL clinical trial of galinpepimut-S (GPS) for acute myeloid leukemia. The event will feature company leadership including President and CEO Angelos Stergiou and expert M. Yair Levy from Baylor University Medical Center. GPS targets the WT1 protein, with potential applications in various cancer types. The company is also developing GFH009, a selective CDK9 inhibitor, licensed from GenFleet Therapeutics.
- Upcoming virtual investor event to discuss Phase 3 REGAL trial for GPS.
- GPS shows potential in treating a broad spectrum of cancer types.
- Development of GFH009, a selective CDK9 inhibitor, expands product pipeline.
- None.
NEW YORK, Nov. 02, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today provides webcast information for its virtual investor event on November 14, 2022, at 8:30 a.m. ET. at which the Company will provide an update on its Phase 3 REGAL clinical trial of galinpepimut-S (GPS) in patients with acute myeloid leukemia.
The event will be facilitated by SELLAS management, including SELLAS’ President and CEO, Angelos Stergiou, MD, ScD h.c., and Dragan Cicic, MD, Senior Vice President, Clinical Development, who will be joined by leading cancer researcher, M. Yair Levy, M.D., Director of Hematologic Malignancies Research at the Baylor University Medical Center, and member of the REGAL Steering Committee.
Webcast Information
To attend the live video webcast, please register or email KCSA Strategic Communications at SELLAS@kcsa.com.
About SELLAS Life Sciences Group, Inc.
SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. SELLAS’ lead product candidate, GPS, is licensed from Memorial Sloan Kettering Cancer Center and targets the WT1 protein, which is present in an array of tumor types. GPS has potential as a monotherapy or in combination with other therapies to address a broad spectrum of hematologic malignancies and solid tumor indications. The Company is also developing GFH009, a small molecule, highly selective CDK9 inhibitor, which is licensed from GenFleet Therapeutics (Shanghai), Inc., for all therapeutic and diagnostic uses in the world outside of Greater China.
For more information on SELLAS, please visit www.sellaslifesciences.com.
Forward-Looking Statements
This press release contains forward-looking statements. All statements other than statements of historical facts are “forward-looking statements,” including those relating to future events Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various important factors. The forward-looking statements herein are made only as of the date hereof. SELLAS undertakes no obligation to update or supplement any forward-looking statements to reflect actual results, new information, future events, changes in its expectations or other circumstances that exist after the date as of which the forward-looking statements were made.
Investor Contact
Allison Soss
KCSA Strategic Communications
Email: SELLAS@kcsa.com
Phone: 212.896.1267
Media Contact
Raquel Cona / Michaela Fawcett
KCSA Strategic Communications
Email: SELLAS@kcsa.com
Phone: 516.779.2630
FAQ
What is the purpose of the Phase 3 REGAL clinical trial for SLS?
When is the SELLAS investor event scheduled?
Who will present during the SELLAS investor event?
What are the key products being developed by SELLAS?
What is the target of the GPS therapy?
